Preclinical data on GITR-agonist monoclonal antibodies demonstrated in vitro and in vivo antitumor activity which enhances the CD8+ and CD4+ effector T cells and decreases tumour-infiltrating Tregs (72). The gene discussed is CD4; the disease is neoplasm.